Immuneering Leads The Pack Of 3 US Penny Stocks To Consider

As the S&P 500 nears record highs, fueled by a surge in AI stocks and robust earnings reports, investors are keenly observing opportunities across various market segments. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$110.92M	★★★★★★
BAB (OTCPK:BABB)	$0.87505	$6.41M	★★★★★★
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.87	$12M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.97	$2.09B	★★★★☆☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.2896	$11.03M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.925	$89.18M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$3.12	$59.16M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.28	$22.17M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9272	$82.51M	★★★★★☆

Click here to see the full list of 709 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Immuneering (NasdaqGM:IMRX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Immuneering Corporation is a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients, with a market cap of $65.83 million.

Operations: Immuneering Corporation does not report any revenue segments as it is a clinical-stage oncology company.

Market Cap: $65.83M

Immuneering Corporation, with a market cap of US$65.83 million, remains pre-revenue as it advances its clinical-stage oncology endeavors. The company is debt-free and has experienced management and board teams but faces challenges with less than a year of cash runway. Recent updates from Phase 2a trials showed promising results in pancreatic cancer treatments, achieving higher response rates compared to standard therapies while maintaining tolerability. Despite these advancements, Immuneering's earnings are forecast to decline over the next three years, and it remains unprofitable without significant revenue streams expected in the near term.

• Get an in-depth perspective on Immuneering's performance by reading our balance sheet health report here.
• Explore Immuneering's analyst forecasts in our growth report.

Pixelworks (NasdaqGM:PXLW)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Pixelworks, Inc. develops and markets semiconductor and software solutions for mobile, home and enterprise, and cinema markets across the United States, Japan, China, Taiwan, Korea, and Europe with a market cap of $50.07 million.

Operations: The company generates $54.19 million in revenue from the design, development, marketing, and sale of integrated circuit solutions.

Market Cap: $50.07M

Pixelworks, Inc., with a market cap of US$50.07 million, is currently unprofitable and has seen increasing losses over the past five years at 9.3% annually. Despite this, the company maintains a strong financial position with short-term assets exceeding both short- and long-term liabilities and remains debt-free. Analysts anticipate significant stock price growth potential, estimating a 105% increase. Recent earnings reports show declining sales year-over-year; however, revenue for Q4 2024 is projected between US$9 million and US$10 million. The company recently filed for a US$10 million follow-on equity offering to bolster its financial stability further.

• Jump into the full analysis health report here for a deeper understanding of Pixelworks.
• Understand Pixelworks' earnings outlook by examining our growth report.

Birchtech (OTCPK:BCHT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Birchtech Corp. is an environmental services and technology company that develops and delivers solutions to the power industry both in the United States and internationally, with a market cap of $50.97 million.

Operations: The company's revenue is derived from its Industrial Automation & Controls segment, totaling $16.22 million.

Market Cap: $50.97M

Birchtech Corp., with a market cap of US$50.97 million, is an environmental services and technology company catering to the power industry. Despite being unprofitable, it has reduced losses by 42.5% annually over five years and maintains a debt-free status with short-term assets of US$7.6 million exceeding both short- and long-term liabilities. The company reported Q3 2024 sales at US$5.24 million, down from the previous year, but retains a cash runway exceeding three years due to positive free cash flow growth of 68.8% annually. Recent governance changes include appointing Mitzi H. Coogler as Director and authorizing potential reverse stock split measures.

• Click here to discover the nuances of Birchtech with our detailed analytical financial health report.
• Examine Birchtech's past performance report to understand how it has performed in prior years.

Taking Advantage

• Investigate our full lineup of 709 US Penny Stocks right here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com